Therefore, as a multitarget oral receptor tyrosine kinase (RTK) inhibitor, sunitinib malate (SU11248) has been used as an anticancer drug, which was approved by the FDA in renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors [40,41]. Here, NTRK1 is linked to renal cell carcinoma.